术前调强放疗联合同期卡培他滨化疗的新辅助放化疗在进展期胃癌的应用

Application of Preoperative Intensity-modulated Radiotherapy Combined with Neoadjuvant Radiotherapy with Capecitabine Chemotherapy in Advanced Gastric Cancer

目的观察术前调强放疗联合同期卡培他滨化疗的新辅助放化疗在进展期胃癌的应用效果。方法选取该院84例进展期胃癌患者,采用随机数字表法分组,各42例。对照组予以术前卡培他滨联合奥沙利铂的新辅助化疗,观察组予以术前卡培他滨联合调强放疗的新辅助放化疗。对比两组客观缓解率(ORR)、不良反应发生情况、生存情况。结果观察组ORR 66.67%(28/42)较对照组45.24%(19/42)高(P<0.05);观察组不良反应发生率11.90%(5/42)与对照组7.14%(3/42)对比差异无统计学意义(P>0.05);观察组1年生存率80.95%(34/42)较对照组59.52%(25/42)高,2年生存率73.81%(31/42)较对照组52.38%(22/42)高,局部复发率4.76%(2/42)较对照组23.81%(10/42)低,远处转移率9.52%(4/42)较对照组28.57%(12/42)低(P<0.05)。结论术前调强放疗联合同期卡培他滨化疗的新辅助放化疗治疗进展期胃癌,可提高治疗效果,改善患者生存率,减少局部复发、远处转移,安全性高。

Objective To observe the effect of preoperative intensity-modulated radiotherapy combined with neoadjuvant chemotherapy with capecitabine in advanced gastric cancer. Methods Convenient select eighty-four patients with advanced gastric cancer were enrolled in our hospital. They were randomly divided into two groups, with 42 cases in each group. The control group received neoadjuvant chemotherapy with capecitabine plus oxaliplatin before surgery. The observation group received neoadjuvant chemoradiation with preoperative capecitabine combined with intensity-modulated radiotherapy. Results The ORR of the observation group was 66.67%(28/42) higher than that of the control group was 45.24%(19/42)(P<0.05). The incidence of adverse reactions in the observation group was 11.90%(5/42) and the control group was 7.14%(3/42). There the difference was statistically significant(P>0.05). The 1-year survival rate of the observation group was 80.95%(34/42) higher than that of the control group was 59.52%(25/42), and the 2-year survival rate was 73.81%(31/42) compared with the control group. 52.38%(22/42) high, local recurrence rate was 4.76%(2/42) lower than 23.81%(10/42) in the control group, and distant metastasis rate was 9.52%(4/42) compared with 28.57%(12/42) in the control group (P< 0.05). Conclusion Preoperative intensity-modulated radiotherapy combined with neoadjuvant radiotherapy combined with capecitabine chemotherapy for advanced gastric cancer can improve the treatment effect, improve patient survival rate, reduce local recurrence, distant metastasis, and have high safety.